PET/CT of cranial arteries for a sensitive diagnosis of giant cell arteritis.


Journal

Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501

Informations de publication

Date de publication:
03 04 2023
Historique:
received: 03 05 2022
accepted: 17 07 2022
medline: 5 4 2023
pubmed: 23 7 2022
entrez: 22 7 2022
Statut: ppublish

Résumé

To investigate the performance of cranial PET/CT for the diagnosis of GCA. All patients with a suspected diagnosis of GCA were prospectively enrolled in this study and had a digital PET/CT with evaluation of cranial arteries if they had not started glucocorticoids >72 h previously. The diagnosis of GCA was retained after at least 6 months of follow-up if no other diagnosis was considered by the clinician and the patient went into remission after at least 6 consecutive months of treatment. Cranial PET/CT was considered positive if at least one arterial segment showed hypermetabolism similar to or greater than liver uptake. For cranial PET/CT, sensitivity (Se), specificity (Sp), positive predictive value (PPV) and negative predictive value (NPV) were 73.3%, 97.2%, 91.7% and 89.7%, respectively. For extracranial PET/CT, diagnostic performance was lower (Se = 66.7%, Sp = 80.6%, PPV = 58.8%, NPV = 85.3%). The combination of cranial and extracranial PET/CT improved overall sensitivity (Se = 80%) and NPV (NPV = 90.3%) while decreasing overall specificity (Sp = 77.8%) and PPV (PPV = 60%). Cranial PET/CT can be easily combined with extracranial PET/CT with a limited increase in examination time. Combined cranial and extracranial PET/CT showed very high diagnostic accuracy for the diagnosis of GCA. ClinicalTrials.gov, https://clinicaltrials.gov, NCT05246540.

Identifiants

pubmed: 35866984
pii: 6648471
doi: 10.1093/rheumatology/keac430
doi:

Substances chimiques

Fluorodeoxyglucose F18 0Z5B2CJX4D

Banques de données

ClinicalTrials.gov
['NCT05246540']

Types de publication

Clinical Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1568-1575

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Thomas Thibault (T)

Department of Internal Medicine and Clinical Immunology, Dijon University Hospital.

Bastien Durand-Bailloud (B)

Department of Nuclear Medicine, Centre Georges François Leclerc.

Agnès Soudry-Faure (A)

Direction of Clinical Research and Innovation (DRCI), Clinical Research Unit-Methodological Support Network (USMR).

Hélène Greigert (H)

Department of Internal Medicine and Clinical Immunology, Dijon University Hospital.
Department of Vascular Medicine, Dijon University Hospital.
INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon Hôte-Tumeur/Ingénierie Cellulaire et Génique, Université Bourgogne Franche-Comté.

Clément Drouet (C)

Department of Nuclear Medicine, Centre Georges François Leclerc.

Hervé Devilliers (H)

Department of Internal Medicine and Systemic Diseases.

André Ramon (A)

Department of Rheumatology.

Laurent Martin (L)

Department of Pathology.

Catherine Creuzot-Garcher (C)

Department of Ophthalmology.

Nicolas Falvo (N)

Department of Internal Medicine and Clinical Immunology, Dijon University Hospital.

Sylvain Audia (S)

Department of Internal Medicine and Clinical Immunology, Dijon University Hospital.
INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon Hôte-Tumeur/Ingénierie Cellulaire et Génique, Université Bourgogne Franche-Comté.

Alexandre Cochet (A)

Department of Nuclear Medicine, Centre Georges François Leclerc.
Department of Nuclear Medicine, Dijon University Hospital.
ImViA EA 7535, Université Bourgogne Franche-Comté, Dijon, France.

Bernard Bonnotte (B)

Department of Internal Medicine and Clinical Immunology, Dijon University Hospital.
INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon Hôte-Tumeur/Ingénierie Cellulaire et Génique, Université Bourgogne Franche-Comté.

Jean-Louis Alberini (JL)

Department of Nuclear Medicine, Centre Georges François Leclerc.
Department of Nuclear Medicine, Dijon University Hospital.
ImViA EA 7535, Université Bourgogne Franche-Comté, Dijon, France.

Maxime Samson (M)

Department of Internal Medicine and Clinical Immunology, Dijon University Hospital.
INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon Hôte-Tumeur/Ingénierie Cellulaire et Génique, Université Bourgogne Franche-Comté.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH